nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—CYP3A7—Delavirdine—acquired immunodeficiency syndrome	0.0264	0.0431	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Delavirdine—acquired immunodeficiency syndrome	0.0264	0.0431	CbGbCtD
Ziprasidone—CYP3A7—Indinavir—acquired immunodeficiency syndrome	0.0228	0.0372	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Indinavir—acquired immunodeficiency syndrome	0.0228	0.0372	CbGbCtD
Ziprasidone—CYP3A7—Nelfinavir—acquired immunodeficiency syndrome	0.0222	0.0361	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Nelfinavir—acquired immunodeficiency syndrome	0.0222	0.0361	CbGbCtD
Ziprasidone—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0219	0.0357	CbGbCtD
Ziprasidone—CYP3A7—Saquinavir—acquired immunodeficiency syndrome	0.02	0.0327	CbGbCtD
Ziprasidone—CYP3A7—Ritonavir—acquired immunodeficiency syndrome	0.02	0.0327	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Saquinavir—acquired immunodeficiency syndrome	0.02	0.0327	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Ritonavir—acquired immunodeficiency syndrome	0.02	0.0327	CbGbCtD
Ziprasidone—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0198	0.0323	CbGbCtD
Ziprasidone—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0198	0.0323	CbGbCtD
Ziprasidone—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0174	0.0283	CbGbCtD
Ziprasidone—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.0171	0.0279	CbGbCtD
Ziprasidone—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0166	0.0271	CbGbCtD
Ziprasidone—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0163	0.0266	CbGbCtD
Ziprasidone—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0163	0.0266	CbGbCtD
Ziprasidone—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.015	0.0245	CbGbCtD
Ziprasidone—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.015	0.0245	CbGbCtD
Ziprasidone—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0148	0.0241	CbGbCtD
Ziprasidone—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0143	0.0233	CbGbCtD
Ziprasidone—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0135	0.0219	CbGbCtD
Ziprasidone—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0135	0.0219	CbGbCtD
Ziprasidone—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0124	0.0202	CbGbCtD
Ziprasidone—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0122	0.0198	CbGbCtD
Ziprasidone—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0122	0.0198	CbGbCtD
Ziprasidone—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0112	0.0182	CbGbCtD
Ziprasidone—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0105	0.0171	CbGbCtD
Ziprasidone—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0102	0.0166	CbGbCtD
Ziprasidone—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00922	0.015	CbGbCtD
Ziprasidone—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00922	0.015	CbGbCtD
Ziprasidone—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0091	0.0148	CbGbCtD
Ziprasidone—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00855	0.0139	CbGbCtD
Ziprasidone—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00855	0.0139	CbGbCtD
Ziprasidone—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00774	0.0126	CbGbCtD
Ziprasidone—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00774	0.0126	CbGbCtD
Ziprasidone—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00668	0.0109	CbGbCtD
Ziprasidone—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00648	0.0106	CbGbCtD
Ziprasidone—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00586	0.00955	CbGbCtD
Ziprasidone—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00586	0.00955	CbGbCtD
Ziprasidone—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00562	0.00916	CbGbCtD
Ziprasidone—H1F0—semen—acquired immunodeficiency syndrome	0.00399	0.0573	CbGeAlD
Ziprasidone—DRD1—nerve—acquired immunodeficiency syndrome	0.0019	0.0272	CbGeAlD
Ziprasidone—HTR3A—nerve—acquired immunodeficiency syndrome	0.00183	0.0263	CbGeAlD
Ziprasidone—HTR7—nerve—acquired immunodeficiency syndrome	0.00119	0.017	CbGeAlD
Ziprasidone—DRD2—nerve—acquired immunodeficiency syndrome	0.00112	0.0161	CbGeAlD
Ziprasidone—SLC6A4—blood plasma—acquired immunodeficiency syndrome	0.00106	0.0152	CbGeAlD
Ziprasidone—HTR7—endothelium—acquired immunodeficiency syndrome	0.00101	0.0145	CbGeAlD
Ziprasidone—HTR1A—blood plasma—acquired immunodeficiency syndrome	0.000938	0.0135	CbGeAlD
Ziprasidone—HTR7—blood plasma—acquired immunodeficiency syndrome	0.000897	0.0129	CbGeAlD
Ziprasidone—CHRM5—skin of body—acquired immunodeficiency syndrome	0.00081	0.0116	CbGeAlD
Ziprasidone—H1F0—retina—acquired immunodeficiency syndrome	0.000796	0.0114	CbGeAlD
Ziprasidone—HTR2A—nerve—acquired immunodeficiency syndrome	0.000739	0.0106	CbGeAlD
Ziprasidone—DRD5—lymphoid tissue—acquired immunodeficiency syndrome	0.000731	0.0105	CbGeAlD
Ziprasidone—HTR1E—nervous system—acquired immunodeficiency syndrome	0.000731	0.0105	CbGeAlD
Ziprasidone—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000715	0.0103	CbGeAlD
Ziprasidone—HTR1E—central nervous system—acquired immunodeficiency syndrome	0.000704	0.0101	CbGeAlD
Ziprasidone—H1F0—skin of body—acquired immunodeficiency syndrome	0.000698	0.01	CbGeAlD
Ziprasidone—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.00069	0.0099	CbGeAlD
Ziprasidone—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.000658	0.00944	CbGeAlD
Ziprasidone—DRD4—brain—acquired immunodeficiency syndrome	0.000648	0.0093	CbGeAlD
Ziprasidone—CHRM4—nervous system—acquired immunodeficiency syndrome	0.000641	0.0092	CbGeAlD
Ziprasidone—HTR2A—endothelium—acquired immunodeficiency syndrome	0.00063	0.00904	CbGeAlD
Ziprasidone—CHRM4—central nervous system—acquired immunodeficiency syndrome	0.000617	0.00886	CbGeAlD
Ziprasidone—DRD3—nervous system—acquired immunodeficiency syndrome	0.000596	0.00856	CbGeAlD
Ziprasidone—DRD3—central nervous system—acquired immunodeficiency syndrome	0.000574	0.00824	CbGeAlD
Ziprasidone—HTR6—nervous system—acquired immunodeficiency syndrome	0.000574	0.00824	CbGeAlD
Ziprasidone—H1F0—lymphoid tissue—acquired immunodeficiency syndrome	0.000566	0.00812	CbGeAlD
Ziprasidone—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.000559	0.00803	CbGeAlD
Ziprasidone—HTR1E—brain—acquired immunodeficiency syndrome	0.000559	0.00802	CbGeAlD
Ziprasidone—H1F0—digestive system—acquired immunodeficiency syndrome	0.000559	0.00802	CbGeAlD
Ziprasidone—DRD5—nervous system—acquired immunodeficiency syndrome	0.000558	0.00802	CbGeAlD
Ziprasidone—HTR6—central nervous system—acquired immunodeficiency syndrome	0.000552	0.00793	CbGeAlD
Ziprasidone—DRD5—central nervous system—acquired immunodeficiency syndrome	0.000538	0.00772	CbGeAlD
Ziprasidone—HTR3A—digestive system—acquired immunodeficiency syndrome	0.000533	0.00765	CbGeAlD
Ziprasidone—H1F0—blood—acquired immunodeficiency syndrome	0.000532	0.00764	CbGeAlD
Ziprasidone—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000518	0.00743	CbGeAlD
Ziprasidone—H1F0—bone marrow—acquired immunodeficiency syndrome	0.000515	0.0074	CbGeAlD
Ziprasidone—H1F0—spinal cord—acquired immunodeficiency syndrome	0.000513	0.00736	CbGeAlD
Ziprasidone—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000509	0.00731	CbGeAlD
Ziprasidone—HTR3A—blood—acquired immunodeficiency syndrome	0.000508	0.00729	CbGeAlD
Ziprasidone—CHRM5—nervous system—acquired immunodeficiency syndrome	0.000501	0.00719	CbGeAlD
Ziprasidone—H1F0—vagina—acquired immunodeficiency syndrome	0.000493	0.00708	CbGeAlD
Ziprasidone—CHRM4—brain—acquired immunodeficiency syndrome	0.00049	0.00703	CbGeAlD
Ziprasidone—CHRM5—central nervous system—acquired immunodeficiency syndrome	0.000482	0.00693	CbGeAlD
Ziprasidone—H1F0—lung—acquired immunodeficiency syndrome	0.000467	0.0067	CbGeAlD
Ziprasidone—DRD2—retina—acquired immunodeficiency syndrome	0.000464	0.00667	CbGeAlD
Ziprasidone—ADRA1B—nervous system—acquired immunodeficiency syndrome	0.000458	0.00657	CbGeAlD
Ziprasidone—DRD3—brain—acquired immunodeficiency syndrome	0.000455	0.00654	CbGeAlD
Ziprasidone—HTR3A—lung—acquired immunodeficiency syndrome	0.000445	0.00639	CbGeAlD
Ziprasidone—ADRA1B—central nervous system—acquired immunodeficiency syndrome	0.000441	0.00633	CbGeAlD
Ziprasidone—HTR6—brain—acquired immunodeficiency syndrome	0.000438	0.0063	CbGeAlD
Ziprasidone—H1F0—nervous system—acquired immunodeficiency syndrome	0.000432	0.0062	CbGeAlD
Ziprasidone—DRD5—brain—acquired immunodeficiency syndrome	0.000427	0.00613	CbGeAlD
Ziprasidone—DRD1—nervous system—acquired immunodeficiency syndrome	0.000427	0.00613	CbGeAlD
Ziprasidone—H1F0—central nervous system—acquired immunodeficiency syndrome	0.000416	0.00597	CbGeAlD
Ziprasidone—HTR3A—nervous system—acquired immunodeficiency syndrome	0.000412	0.00592	CbGeAlD
Ziprasidone—DRD1—central nervous system—acquired immunodeficiency syndrome	0.000411	0.0059	CbGeAlD
Ziprasidone—HTR1B—spinal cord—acquired immunodeficiency syndrome	0.00041	0.00589	CbGeAlD
Ziprasidone—SLC6A4—digestive system—acquired immunodeficiency syndrome	0.000406	0.00583	CbGeAlD
Ziprasidone—HTR3A—central nervous system—acquired immunodeficiency syndrome	0.000397	0.0057	CbGeAlD
Ziprasidone—HTR2C—spinal cord—acquired immunodeficiency syndrome	0.000393	0.00565	CbGeAlD
Ziprasidone—SLC6A4—blood—acquired immunodeficiency syndrome	0.000387	0.00556	CbGeAlD
Ziprasidone—CHRM5—brain—acquired immunodeficiency syndrome	0.000383	0.0055	CbGeAlD
Ziprasidone—SLC6A4—spinal cord—acquired immunodeficiency syndrome	0.000373	0.00535	CbGeAlD
Ziprasidone—CHRM3—digestive system—acquired immunodeficiency syndrome	0.000362	0.0052	CbGeAlD
Ziprasidone—ADRA1B—brain—acquired immunodeficiency syndrome	0.00035	0.00502	CbGeAlD
Ziprasidone—HTR1B—nervous system—acquired immunodeficiency syndrome	0.000346	0.00496	CbGeAlD
Ziprasidone—HTR7—digestive system—acquired immunodeficiency syndrome	0.000345	0.00495	CbGeAlD
Ziprasidone—CHRM2—nervous system—acquired immunodeficiency syndrome	0.000344	0.00494	CbGeAlD
Ziprasidone—SLC6A4—lung—acquired immunodeficiency syndrome	0.000339	0.00487	CbGeAlD
Ziprasidone—CHRM1—lung—acquired immunodeficiency syndrome	0.000338	0.00485	CbGeAlD
Ziprasidone—ADRA1A—lymphoid tissue—acquired immunodeficiency syndrome	0.000337	0.00483	CbGeAlD
Ziprasidone—HTR1D—nervous system—acquired immunodeficiency syndrome	0.000335	0.00481	CbGeAlD
Ziprasidone—HTR1B—central nervous system—acquired immunodeficiency syndrome	0.000333	0.00478	CbGeAlD
Ziprasidone—HTR2C—nervous system—acquired immunodeficiency syndrome	0.000331	0.00476	CbGeAlD
Ziprasidone—HTR1A—spinal cord—acquired immunodeficiency syndrome	0.000331	0.00475	CbGeAlD
Ziprasidone—CHRM2—central nervous system—acquired immunodeficiency syndrome	0.000331	0.00475	CbGeAlD
Ziprasidone—H1F0—brain—acquired immunodeficiency syndrome	0.00033	0.00474	CbGeAlD
Ziprasidone—HTR7—blood—acquired immunodeficiency syndrome	0.000328	0.00472	CbGeAlD
Ziprasidone—DRD1—brain—acquired immunodeficiency syndrome	0.000326	0.00468	CbGeAlD
Ziprasidone—HTR1D—central nervous system—acquired immunodeficiency syndrome	0.000322	0.00463	CbGeAlD
Ziprasidone—H1F0—lymph node—acquired immunodeficiency syndrome	0.000319	0.00458	CbGeAlD
Ziprasidone—HTR2C—central nervous system—acquired immunodeficiency syndrome	0.000319	0.00458	CbGeAlD
Ziprasidone—ADRA1A—blood—acquired immunodeficiency syndrome	0.000317	0.00455	CbGeAlD
Ziprasidone—HTR7—spinal cord—acquired immunodeficiency syndrome	0.000316	0.00454	CbGeAlD
Ziprasidone—HTR3A—brain—acquired immunodeficiency syndrome	0.000315	0.00452	CbGeAlD
Ziprasidone—SLC6A4—nervous system—acquired immunodeficiency syndrome	0.000314	0.00451	CbGeAlD
Ziprasidone—CHRM1—nervous system—acquired immunodeficiency syndrome	0.000313	0.00449	CbGeAlD
Ziprasidone—HTR2A—retina—acquired immunodeficiency syndrome	0.000306	0.0044	CbGeAlD
Ziprasidone—KCNH2—blood—acquired immunodeficiency syndrome	0.000306	0.00439	CbGeAlD
Ziprasidone—SLC6A4—central nervous system—acquired immunodeficiency syndrome	0.000303	0.00434	CbGeAlD
Ziprasidone—ADRA2C—blood—acquired immunodeficiency syndrome	0.000302	0.00433	CbGeAlD
Ziprasidone—CHRM1—central nervous system—acquired immunodeficiency syndrome	0.000301	0.00433	CbGeAlD
Ziprasidone—KCNH2—bone marrow—acquired immunodeficiency syndrome	0.000296	0.00425	CbGeAlD
Ziprasidone—KCNH2—spinal cord—acquired immunodeficiency syndrome	0.000295	0.00423	CbGeAlD
Ziprasidone—ADRA2C—spinal cord—acquired immunodeficiency syndrome	0.000291	0.00418	CbGeAlD
Ziprasidone—HTR7—lung—acquired immunodeficiency syndrome	0.000288	0.00413	CbGeAlD
Ziprasidone—KCNH2—vagina—acquired immunodeficiency syndrome	0.000284	0.00407	CbGeAlD
Ziprasidone—CHRM3—nervous system—acquired immunodeficiency syndrome	0.00028	0.00402	CbGeAlD
Ziprasidone—ADRA2C—vagina—acquired immunodeficiency syndrome	0.00028	0.00402	CbGeAlD
Ziprasidone—HTR1A—nervous system—acquired immunodeficiency syndrome	0.000279	0.00401	CbGeAlD
Ziprasidone—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000275	0.00395	CbGeAlD
Ziprasidone—DRD2—lung—acquired immunodeficiency syndrome	0.000272	0.00391	CbGeAlD
Ziprasidone—CHRM3—central nervous system—acquired immunodeficiency syndrome	0.00027	0.00387	CbGeAlD
Ziprasidone—HTR1A—central nervous system—acquired immunodeficiency syndrome	0.000269	0.00386	CbGeAlD
Ziprasidone—HTR7—nervous system—acquired immunodeficiency syndrome	0.000267	0.00383	CbGeAlD
Ziprasidone—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000265	0.00381	CbGeAlD
Ziprasidone—ADRA2C—lung—acquired immunodeficiency syndrome	0.000265	0.0038	CbGeAlD
Ziprasidone—HTR1B—brain—acquired immunodeficiency syndrome	0.000264	0.00379	CbGeAlD
Ziprasidone—CHRM2—brain—acquired immunodeficiency syndrome	0.000263	0.00377	CbGeAlD
Ziprasidone—CYP1A2—blood—acquired immunodeficiency syndrome	0.000262	0.00376	CbGeAlD
Ziprasidone—HRH1—digestive system—acquired immunodeficiency syndrome	0.000257	0.0037	CbGeAlD
Ziprasidone—ADRA1A—nervous system—acquired immunodeficiency syndrome	0.000257	0.00369	CbGeAlD
Ziprasidone—HTR7—central nervous system—acquired immunodeficiency syndrome	0.000257	0.00369	CbGeAlD
Ziprasidone—HTR1D—brain—acquired immunodeficiency syndrome	0.000256	0.00367	CbGeAlD
Ziprasidone—HTR2C—brain—acquired immunodeficiency syndrome	0.000253	0.00364	CbGeAlD
Ziprasidone—CYP3A5—blood—acquired immunodeficiency syndrome	0.000253	0.00363	CbGeAlD
Ziprasidone—DRD2—nervous system—acquired immunodeficiency syndrome	0.000252	0.00362	CbGeAlD
Ziprasidone—KCNH2—nervous system—acquired immunodeficiency syndrome	0.000248	0.00357	CbGeAlD
Ziprasidone—ADRA1A—central nervous system—acquired immunodeficiency syndrome	0.000248	0.00356	CbGeAlD
Ziprasidone—ADRA2C—nervous system—acquired immunodeficiency syndrome	0.000245	0.00352	CbGeAlD
Ziprasidone—DRD2—central nervous system—acquired immunodeficiency syndrome	0.000243	0.00349	CbGeAlD
Ziprasidone—ADRA2A—blood—acquired immunodeficiency syndrome	0.000241	0.00346	CbGeAlD
Ziprasidone—SLC6A4—brain—acquired immunodeficiency syndrome	0.00024	0.00345	CbGeAlD
Ziprasidone—CHRM1—brain—acquired immunodeficiency syndrome	0.000239	0.00344	CbGeAlD
Ziprasidone—KCNH2—central nervous system—acquired immunodeficiency syndrome	0.000239	0.00343	CbGeAlD
Ziprasidone—ADRA2C—central nervous system—acquired immunodeficiency syndrome	0.000236	0.00339	CbGeAlD
Ziprasidone—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000234	0.00336	CbGeAlD
Ziprasidone—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.000232	0.00333	CbGeAlD
Ziprasidone—CYP1A2—lung—acquired immunodeficiency syndrome	0.00023	0.0033	CbGeAlD
Ziprasidone—HRH1—vagina—acquired immunodeficiency syndrome	0.000227	0.00326	CbGeAlD
Ziprasidone—ADRA2A—vagina—acquired immunodeficiency syndrome	0.000223	0.00321	CbGeAlD
Ziprasidone—CYP3A5—lung—acquired immunodeficiency syndrome	0.000221	0.00318	CbGeAlD
Ziprasidone—HTR2A—digestive system—acquired immunodeficiency syndrome	0.000215	0.00309	CbGeAlD
Ziprasidone—HRH1—lung—acquired immunodeficiency syndrome	0.000215	0.00309	CbGeAlD
Ziprasidone—CHRM3—brain—acquired immunodeficiency syndrome	0.000214	0.00307	CbGeAlD
Ziprasidone—HTR1A—brain—acquired immunodeficiency syndrome	0.000213	0.00306	CbGeAlD
Ziprasidone—ADRA2A—lung—acquired immunodeficiency syndrome	0.000211	0.00303	CbGeAlD
Ziprasidone—HTR2A—blood—acquired immunodeficiency syndrome	0.000205	0.00294	CbGeAlD
Ziprasidone—HTR7—brain—acquired immunodeficiency syndrome	0.000204	0.00293	CbGeAlD
Ziprasidone—HRH1—nervous system—acquired immunodeficiency syndrome	0.000199	0.00286	CbGeAlD
Ziprasidone—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000199	0.00286	CbGeAlD
Ziprasidone—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000197	0.00283	CbGeAlD
Ziprasidone—ADRA1A—brain—acquired immunodeficiency syndrome	0.000197	0.00282	CbGeAlD
Ziprasidone—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000196	0.00281	CbGeAlD
Ziprasidone—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.000196	0.00281	CbGeAlD
Ziprasidone—DRD2—brain—acquired immunodeficiency syndrome	0.000193	0.00277	CbGeAlD
Ziprasidone—HRH1—central nervous system—acquired immunodeficiency syndrome	0.000192	0.00275	CbGeAlD
Ziprasidone—HTR2A—vagina—acquired immunodeficiency syndrome	0.00019	0.00273	CbGeAlD
Ziprasidone—KCNH2—brain—acquired immunodeficiency syndrome	0.00019	0.00273	CbGeAlD
Ziprasidone—CYP3A4—blood—acquired immunodeficiency syndrome	0.00019	0.00272	CbGeAlD
Ziprasidone—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.000188	0.0027	CbGeAlD
Ziprasidone—ADRA2C—brain—acquired immunodeficiency syndrome	0.000187	0.00269	CbGeAlD
Ziprasidone—CYP2D6—blood—acquired immunodeficiency syndrome	0.000187	0.00268	CbGeAlD
Ziprasidone—KCNH2—lymph node—acquired immunodeficiency syndrome	0.000183	0.00263	CbGeAlD
Ziprasidone—ADRA2C—lymph node—acquired immunodeficiency syndrome	0.000181	0.0026	CbGeAlD
Ziprasidone—HTR2A—lung—acquired immunodeficiency syndrome	0.00018	0.00258	CbGeAlD
Ziprasidone—HTR2A—nervous system—acquired immunodeficiency syndrome	0.000166	0.00239	CbGeAlD
Ziprasidone—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.00016	0.0023	CbGeAlD
Ziprasidone—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000154	0.00221	CbGeAlD
Ziprasidone—HRH1—brain—acquired immunodeficiency syndrome	0.000152	0.00219	CbGeAlD
Ziprasidone—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000151	0.00218	CbGeAlD
Ziprasidone—ADRA2A—brain—acquired immunodeficiency syndrome	0.000149	0.00215	CbGeAlD
Ziprasidone—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000148	0.00213	CbGeAlD
Ziprasidone—HRH1—lymph node—acquired immunodeficiency syndrome	0.000147	0.00211	CbGeAlD
Ziprasidone—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000146	0.00209	CbGeAlD
Ziprasidone—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.000144	0.00207	CbGeAlD
Ziprasidone—HTR2A—brain—acquired immunodeficiency syndrome	0.000127	0.00182	CbGeAlD
Ziprasidone—CYP2D6—brain—acquired immunodeficiency syndrome	0.000116	0.00166	CbGeAlD
Ziprasidone—Shock—Delavirdine—acquired immunodeficiency syndrome	9.28e-05	0.000376	CcSEcCtD
Ziprasidone—Somnolence—Indinavir—acquired immunodeficiency syndrome	9.28e-05	0.000376	CcSEcCtD
Ziprasidone—Asthenia—Stavudine—acquired immunodeficiency syndrome	9.26e-05	0.000375	CcSEcCtD
Ziprasidone—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	9.25e-05	0.000374	CcSEcCtD
Ziprasidone—Vertigo—Saquinavir—acquired immunodeficiency syndrome	9.24e-05	0.000374	CcSEcCtD
Ziprasidone—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	9.24e-05	0.000374	CcSEcCtD
Ziprasidone—Hypertension—Ritonavir—acquired immunodeficiency syndrome	9.23e-05	0.000374	CcSEcCtD
Ziprasidone—Syncope—Saquinavir—acquired immunodeficiency syndrome	9.23e-05	0.000374	CcSEcCtD
Ziprasidone—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	9.21e-05	0.000373	CcSEcCtD
Ziprasidone—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	9.21e-05	0.000373	CcSEcCtD
Ziprasidone—Tremor—Lamivudine—acquired immunodeficiency syndrome	9.2e-05	0.000372	CcSEcCtD
Ziprasidone—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	9.19e-05	0.000372	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	9.18e-05	0.000371	CcSEcCtD
Ziprasidone—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	9.16e-05	0.000371	CcSEcCtD
Ziprasidone—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	9.15e-05	0.00037	CcSEcCtD
Ziprasidone—Asthenia—Abacavir—acquired immunodeficiency syndrome	9.12e-05	0.000369	CcSEcCtD
Ziprasidone—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	9.12e-05	0.000369	CcSEcCtD
Ziprasidone—Chest pain—Ritonavir—acquired immunodeficiency syndrome	9.1e-05	0.000368	CcSEcCtD
Ziprasidone—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	9.1e-05	0.000368	CcSEcCtD
Ziprasidone—Myalgia—Ritonavir—acquired immunodeficiency syndrome	9.1e-05	0.000368	CcSEcCtD
Ziprasidone—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	9.07e-05	0.000367	CcSEcCtD
Ziprasidone—Anaemia—Lamivudine—acquired immunodeficiency syndrome	9.07e-05	0.000367	CcSEcCtD
Ziprasidone—Anxiety—Ritonavir—acquired immunodeficiency syndrome	9.07e-05	0.000367	CcSEcCtD
Ziprasidone—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	9.04e-05	0.000366	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	9.04e-05	0.000366	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	9.01e-05	0.000365	CcSEcCtD
Ziprasidone—Fatigue—Indinavir—acquired immunodeficiency syndrome	9e-05	0.000364	CcSEcCtD
Ziprasidone—Anorexia—Delavirdine—acquired immunodeficiency syndrome	8.99e-05	0.000364	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	8.98e-05	0.000364	CcSEcCtD
Ziprasidone—Cough—Saquinavir—acquired immunodeficiency syndrome	8.98e-05	0.000363	CcSEcCtD
Ziprasidone—Angioedema—Lamivudine—acquired immunodeficiency syndrome	8.97e-05	0.000363	CcSEcCtD
Ziprasidone—Constipation—Indinavir—acquired immunodeficiency syndrome	8.92e-05	0.000361	CcSEcCtD
Ziprasidone—Insomnia—Efavirenz—acquired immunodeficiency syndrome	8.92e-05	0.000361	CcSEcCtD
Ziprasidone—Urticaria—Zidovudine—acquired immunodeficiency syndrome	8.91e-05	0.000361	CcSEcCtD
Ziprasidone—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	8.9e-05	0.00036	CcSEcCtD
Ziprasidone—Hypertension—Saquinavir—acquired immunodeficiency syndrome	8.88e-05	0.00036	CcSEcCtD
Ziprasidone—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	8.87e-05	0.000359	CcSEcCtD
Ziprasidone—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	8.87e-05	0.000359	CcSEcCtD
Ziprasidone—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	8.86e-05	0.000359	CcSEcCtD
Ziprasidone—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	8.85e-05	0.000358	CcSEcCtD
Ziprasidone—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	8.83e-05	0.000358	CcSEcCtD
Ziprasidone—Nausea—Didanosine—acquired immunodeficiency syndrome	8.83e-05	0.000358	CcSEcCtD
Ziprasidone—Vertigo—Lamivudine—acquired immunodeficiency syndrome	8.82e-05	0.000357	CcSEcCtD
Ziprasidone—Hypotension—Delavirdine—acquired immunodeficiency syndrome	8.82e-05	0.000357	CcSEcCtD
Ziprasidone—Syncope—Lamivudine—acquired immunodeficiency syndrome	8.8e-05	0.000356	CcSEcCtD
Ziprasidone—Confusional state—Ritonavir—acquired immunodeficiency syndrome	8.8e-05	0.000356	CcSEcCtD
Ziprasidone—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	8.79e-05	0.000356	CcSEcCtD
Ziprasidone—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	8.79e-05	0.000356	CcSEcCtD
Ziprasidone—Somnolence—Efavirenz—acquired immunodeficiency syndrome	8.77e-05	0.000355	CcSEcCtD
Ziprasidone—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	8.76e-05	0.000355	CcSEcCtD
Ziprasidone—Myalgia—Saquinavir—acquired immunodeficiency syndrome	8.76e-05	0.000355	CcSEcCtD
Ziprasidone—Chest pain—Saquinavir—acquired immunodeficiency syndrome	8.76e-05	0.000355	CcSEcCtD
Ziprasidone—Anxiety—Saquinavir—acquired immunodeficiency syndrome	8.73e-05	0.000353	CcSEcCtD
Ziprasidone—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	8.7e-05	0.000352	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	8.7e-05	0.000352	CcSEcCtD
Ziprasidone—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	8.68e-05	0.000351	CcSEcCtD
Ziprasidone—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	8.63e-05	0.000349	CcSEcCtD
Ziprasidone—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	8.6e-05	0.000348	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	8.59e-05	0.000348	CcSEcCtD
Ziprasidone—Shock—Ritonavir—acquired immunodeficiency syndrome	8.58e-05	0.000347	CcSEcCtD
Ziprasidone—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	8.57e-05	0.000347	CcSEcCtD
Ziprasidone—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	8.57e-05	0.000347	CcSEcCtD
Ziprasidone—Cough—Lamivudine—acquired immunodeficiency syndrome	8.56e-05	0.000347	CcSEcCtD
Ziprasidone—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	8.56e-05	0.000347	CcSEcCtD
Ziprasidone—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	8.56e-05	0.000346	CcSEcCtD
Ziprasidone—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	8.54e-05	0.000346	CcSEcCtD
Ziprasidone—Dizziness—Stavudine—acquired immunodeficiency syndrome	8.54e-05	0.000346	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	8.53e-05	0.000345	CcSEcCtD
Ziprasidone—Insomnia—Delavirdine—acquired immunodeficiency syndrome	8.53e-05	0.000345	CcSEcCtD
Ziprasidone—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	8.51e-05	0.000345	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	8.51e-05	0.000345	CcSEcCtD
Ziprasidone—Vomiting—Nevirapine—acquired immunodeficiency syndrome	8.5e-05	0.000344	CcSEcCtD
Ziprasidone—Fatigue—Efavirenz—acquired immunodeficiency syndrome	8.5e-05	0.000344	CcSEcCtD
Ziprasidone—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	8.47e-05	0.000343	CcSEcCtD
Ziprasidone—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	8.47e-05	0.000343	CcSEcCtD
Ziprasidone—Confusional state—Saquinavir—acquired immunodeficiency syndrome	8.47e-05	0.000343	CcSEcCtD
Ziprasidone—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	8.43e-05	0.000341	CcSEcCtD
Ziprasidone—Constipation—Efavirenz—acquired immunodeficiency syndrome	8.43e-05	0.000341	CcSEcCtD
Ziprasidone—Rash—Nevirapine—acquired immunodeficiency syndrome	8.43e-05	0.000341	CcSEcCtD
Ziprasidone—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	8.42e-05	0.000341	CcSEcCtD
Ziprasidone—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	8.41e-05	0.00034	CcSEcCtD
Ziprasidone—Dizziness—Abacavir—acquired immunodeficiency syndrome	8.41e-05	0.00034	CcSEcCtD
Ziprasidone—Somnolence—Delavirdine—acquired immunodeficiency syndrome	8.39e-05	0.00034	CcSEcCtD
Ziprasidone—Headache—Nevirapine—acquired immunodeficiency syndrome	8.38e-05	0.000339	CcSEcCtD
Ziprasidone—Myalgia—Lamivudine—acquired immunodeficiency syndrome	8.36e-05	0.000338	CcSEcCtD
Ziprasidone—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	8.36e-05	0.000338	CcSEcCtD
Ziprasidone—Chest pain—Lamivudine—acquired immunodeficiency syndrome	8.36e-05	0.000338	CcSEcCtD
Ziprasidone—Infection—Saquinavir—acquired immunodeficiency syndrome	8.34e-05	0.000338	CcSEcCtD
Ziprasidone—Anxiety—Lamivudine—acquired immunodeficiency syndrome	8.33e-05	0.000337	CcSEcCtD
Ziprasidone—Anorexia—Ritonavir—acquired immunodeficiency syndrome	8.32e-05	0.000337	CcSEcCtD
Ziprasidone—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	8.3e-05	0.000336	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	8.3e-05	0.000336	CcSEcCtD
Ziprasidone—Urticaria—Indinavir—acquired immunodeficiency syndrome	8.29e-05	0.000336	CcSEcCtD
Ziprasidone—Shock—Saquinavir—acquired immunodeficiency syndrome	8.26e-05	0.000334	CcSEcCtD
Ziprasidone—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	8.25e-05	0.000334	CcSEcCtD
Ziprasidone—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	8.25e-05	0.000334	CcSEcCtD
Ziprasidone—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	8.23e-05	0.000333	CcSEcCtD
Ziprasidone—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	8.23e-05	0.000333	CcSEcCtD
Ziprasidone—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	8.22e-05	0.000333	CcSEcCtD
Ziprasidone—Vomiting—Stavudine—acquired immunodeficiency syndrome	8.21e-05	0.000332	CcSEcCtD
Ziprasidone—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	8.2e-05	0.000332	CcSEcCtD
Ziprasidone—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	8.17e-05	0.000331	CcSEcCtD
Ziprasidone—Rash—Nelfinavir—acquired immunodeficiency syndrome	8.17e-05	0.000331	CcSEcCtD
Ziprasidone—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	8.16e-05	0.00033	CcSEcCtD
Ziprasidone—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	8.16e-05	0.00033	CcSEcCtD
Ziprasidone—Hypotension—Ritonavir—acquired immunodeficiency syndrome	8.15e-05	0.00033	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	8.14e-05	0.00033	CcSEcCtD
Ziprasidone—Rash—Stavudine—acquired immunodeficiency syndrome	8.14e-05	0.00033	CcSEcCtD
Ziprasidone—Fatigue—Delavirdine—acquired immunodeficiency syndrome	8.13e-05	0.000329	CcSEcCtD
Ziprasidone—Dermatitis—Stavudine—acquired immunodeficiency syndrome	8.13e-05	0.000329	CcSEcCtD
Ziprasidone—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	8.12e-05	0.000329	CcSEcCtD
Ziprasidone—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	8.12e-05	0.000329	CcSEcCtD
Ziprasidone—Headache—Nelfinavir—acquired immunodeficiency syndrome	8.11e-05	0.000328	CcSEcCtD
Ziprasidone—Headache—Stavudine—acquired immunodeficiency syndrome	8.09e-05	0.000327	CcSEcCtD
Ziprasidone—Vomiting—Abacavir—acquired immunodeficiency syndrome	8.09e-05	0.000327	CcSEcCtD
Ziprasidone—Confusional state—Lamivudine—acquired immunodeficiency syndrome	8.08e-05	0.000327	CcSEcCtD
Ziprasidone—Constipation—Delavirdine—acquired immunodeficiency syndrome	8.07e-05	0.000327	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	8.06e-05	0.000326	CcSEcCtD
Ziprasidone—Asthenia—Zidovudine—acquired immunodeficiency syndrome	8.05e-05	0.000326	CcSEcCtD
Ziprasidone—Rash—Abacavir—acquired immunodeficiency syndrome	8.02e-05	0.000325	CcSEcCtD
Ziprasidone—Dermatitis—Abacavir—acquired immunodeficiency syndrome	8.01e-05	0.000324	CcSEcCtD
Ziprasidone—Anorexia—Saquinavir—acquired immunodeficiency syndrome	8e-05	0.000324	CcSEcCtD
Ziprasidone—Headache—Abacavir—acquired immunodeficiency syndrome	7.97e-05	0.000323	CcSEcCtD
Ziprasidone—Infection—Lamivudine—acquired immunodeficiency syndrome	7.96e-05	0.000322	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	7.95e-05	0.000322	CcSEcCtD
Ziprasidone—Nausea—Nevirapine—acquired immunodeficiency syndrome	7.94e-05	0.000322	CcSEcCtD
Ziprasidone—Insomnia—Ritonavir—acquired immunodeficiency syndrome	7.89e-05	0.000319	CcSEcCtD
Ziprasidone—Shock—Lamivudine—acquired immunodeficiency syndrome	7.88e-05	0.000319	CcSEcCtD
Ziprasidone—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	7.86e-05	0.000318	CcSEcCtD
Ziprasidone—Hypotension—Saquinavir—acquired immunodeficiency syndrome	7.85e-05	0.000318	CcSEcCtD
Ziprasidone—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	7.84e-05	0.000318	CcSEcCtD
Ziprasidone—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	7.83e-05	0.000317	CcSEcCtD
Ziprasidone—Urticaria—Efavirenz—acquired immunodeficiency syndrome	7.83e-05	0.000317	CcSEcCtD
Ziprasidone—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	7.79e-05	0.000316	CcSEcCtD
Ziprasidone—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	7.79e-05	0.000316	CcSEcCtD
Ziprasidone—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	7.78e-05	0.000315	CcSEcCtD
Ziprasidone—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	7.78e-05	0.000315	CcSEcCtD
Ziprasidone—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	7.77e-05	0.000315	CcSEcCtD
Ziprasidone—Somnolence—Ritonavir—acquired immunodeficiency syndrome	7.76e-05	0.000314	CcSEcCtD
Ziprasidone—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	7.74e-05	0.000313	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	7.71e-05	0.000312	CcSEcCtD
Ziprasidone—Nausea—Nelfinavir—acquired immunodeficiency syndrome	7.69e-05	0.000311	CcSEcCtD
Ziprasidone—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	7.69e-05	0.000311	CcSEcCtD
Ziprasidone—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	7.68e-05	0.000311	CcSEcCtD
Ziprasidone—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	7.68e-05	0.000311	CcSEcCtD
Ziprasidone—Nausea—Stavudine—acquired immunodeficiency syndrome	7.67e-05	0.00031	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	7.65e-05	0.00031	CcSEcCtD
Ziprasidone—Anorexia—Lamivudine—acquired immunodeficiency syndrome	7.64e-05	0.000309	CcSEcCtD
Ziprasidone—Insomnia—Saquinavir—acquired immunodeficiency syndrome	7.59e-05	0.000307	CcSEcCtD
Ziprasidone—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	7.58e-05	0.000307	CcSEcCtD
Ziprasidone—Nausea—Abacavir—acquired immunodeficiency syndrome	7.55e-05	0.000306	CcSEcCtD
Ziprasidone—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	7.54e-05	0.000305	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	7.53e-05	0.000305	CcSEcCtD
Ziprasidone—Fatigue—Ritonavir—acquired immunodeficiency syndrome	7.52e-05	0.000304	CcSEcCtD
Ziprasidone—Urticaria—Delavirdine—acquired immunodeficiency syndrome	7.49e-05	0.000303	CcSEcCtD
Ziprasidone—Asthenia—Indinavir—acquired immunodeficiency syndrome	7.49e-05	0.000303	CcSEcCtD
Ziprasidone—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	7.49e-05	0.000303	CcSEcCtD
Ziprasidone—Hypotension—Lamivudine—acquired immunodeficiency syndrome	7.48e-05	0.000303	CcSEcCtD
Ziprasidone—Somnolence—Saquinavir—acquired immunodeficiency syndrome	7.46e-05	0.000302	CcSEcCtD
Ziprasidone—Constipation—Ritonavir—acquired immunodeficiency syndrome	7.46e-05	0.000302	CcSEcCtD
Ziprasidone—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	7.46e-05	0.000302	CcSEcCtD
Ziprasidone—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	7.46e-05	0.000302	CcSEcCtD
Ziprasidone—Dizziness—Zidovudine—acquired immunodeficiency syndrome	7.42e-05	0.0003	CcSEcCtD
Ziprasidone—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	7.39e-05	0.000299	CcSEcCtD
Ziprasidone—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	7.3e-05	0.000295	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	7.3e-05	0.000295	CcSEcCtD
Ziprasidone—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	7.26e-05	0.000294	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	7.25e-05	0.000293	CcSEcCtD
Ziprasidone—Insomnia—Lamivudine—acquired immunodeficiency syndrome	7.24e-05	0.000293	CcSEcCtD
Ziprasidone—Fatigue—Saquinavir—acquired immunodeficiency syndrome	7.24e-05	0.000293	CcSEcCtD
Ziprasidone—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	7.19e-05	0.000291	CcSEcCtD
Ziprasidone—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	7.19e-05	0.000291	CcSEcCtD
Ziprasidone—Constipation—Saquinavir—acquired immunodeficiency syndrome	7.18e-05	0.000291	CcSEcCtD
Ziprasidone—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	7.14e-05	0.000289	CcSEcCtD
Ziprasidone—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	7.14e-05	0.000289	CcSEcCtD
Ziprasidone—Vomiting—Zidovudine—acquired immunodeficiency syndrome	7.13e-05	0.000289	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	7.13e-05	0.000289	CcSEcCtD
Ziprasidone—Somnolence—Lamivudine—acquired immunodeficiency syndrome	7.12e-05	0.000288	CcSEcCtD
Ziprasidone—Rash—Zidovudine—acquired immunodeficiency syndrome	7.08e-05	0.000286	CcSEcCtD
Ziprasidone—Asthenia—Efavirenz—acquired immunodeficiency syndrome	7.07e-05	0.000286	CcSEcCtD
Ziprasidone—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	7.07e-05	0.000286	CcSEcCtD
Ziprasidone—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	7.05e-05	0.000285	CcSEcCtD
Ziprasidone—Headache—Zidovudine—acquired immunodeficiency syndrome	7.03e-05	0.000285	CcSEcCtD
Ziprasidone—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	6.96e-05	0.000282	CcSEcCtD
Ziprasidone—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	6.95e-05	0.000281	CcSEcCtD
Ziprasidone—Urticaria—Ritonavir—acquired immunodeficiency syndrome	6.93e-05	0.000281	CcSEcCtD
Ziprasidone—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	6.92e-05	0.00028	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	6.92e-05	0.00028	CcSEcCtD
Ziprasidone—Fatigue—Lamivudine—acquired immunodeficiency syndrome	6.91e-05	0.00028	CcSEcCtD
Ziprasidone—Dizziness—Indinavir—acquired immunodeficiency syndrome	6.9e-05	0.000279	CcSEcCtD
Ziprasidone—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	6.9e-05	0.000279	CcSEcCtD
Ziprasidone—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	6.9e-05	0.000279	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	6.87e-05	0.000278	CcSEcCtD
Ziprasidone—Constipation—Lamivudine—acquired immunodeficiency syndrome	6.85e-05	0.000277	CcSEcCtD
Ziprasidone—Asthenia—Delavirdine—acquired immunodeficiency syndrome	6.77e-05	0.000274	CcSEcCtD
Ziprasidone—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	6.75e-05	0.000273	CcSEcCtD
Ziprasidone—Urticaria—Saquinavir—acquired immunodeficiency syndrome	6.67e-05	0.00027	CcSEcCtD
Ziprasidone—Nausea—Zidovudine—acquired immunodeficiency syndrome	6.67e-05	0.00027	CcSEcCtD
Ziprasidone—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	6.64e-05	0.000269	CcSEcCtD
Ziprasidone—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	6.64e-05	0.000269	CcSEcCtD
Ziprasidone—Vomiting—Indinavir—acquired immunodeficiency syndrome	6.64e-05	0.000269	CcSEcCtD
Ziprasidone—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	6.6e-05	0.000267	CcSEcCtD
Ziprasidone—Rash—Indinavir—acquired immunodeficiency syndrome	6.58e-05	0.000266	CcSEcCtD
Ziprasidone—Dermatitis—Indinavir—acquired immunodeficiency syndrome	6.57e-05	0.000266	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	6.55e-05	0.000265	CcSEcCtD
Ziprasidone—Headache—Indinavir—acquired immunodeficiency syndrome	6.54e-05	0.000265	CcSEcCtD
Ziprasidone—Dizziness—Efavirenz—acquired immunodeficiency syndrome	6.52e-05	0.000264	CcSEcCtD
Ziprasidone—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	6.45e-05	0.000261	CcSEcCtD
Ziprasidone—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	6.43e-05	0.00026	CcSEcCtD
Ziprasidone—Urticaria—Lamivudine—acquired immunodeficiency syndrome	6.36e-05	0.000258	CcSEcCtD
Ziprasidone—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	6.33e-05	0.000256	CcSEcCtD
Ziprasidone—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	6.33e-05	0.000256	CcSEcCtD
Ziprasidone—Vomiting—Efavirenz—acquired immunodeficiency syndrome	6.27e-05	0.000254	CcSEcCtD
Ziprasidone—Asthenia—Ritonavir—acquired immunodeficiency syndrome	6.26e-05	0.000253	CcSEcCtD
Ziprasidone—Dizziness—Delavirdine—acquired immunodeficiency syndrome	6.24e-05	0.000253	CcSEcCtD
Ziprasidone—Rash—Efavirenz—acquired immunodeficiency syndrome	6.22e-05	0.000252	CcSEcCtD
Ziprasidone—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	6.21e-05	0.000251	CcSEcCtD
Ziprasidone—Nausea—Indinavir—acquired immunodeficiency syndrome	6.2e-05	0.000251	CcSEcCtD
Ziprasidone—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	6.19e-05	0.00025	CcSEcCtD
Ziprasidone—Headache—Efavirenz—acquired immunodeficiency syndrome	6.18e-05	0.00025	CcSEcCtD
Ziprasidone—Asthenia—Saquinavir—acquired immunodeficiency syndrome	6.02e-05	0.000244	CcSEcCtD
Ziprasidone—Vomiting—Delavirdine—acquired immunodeficiency syndrome	6e-05	0.000243	CcSEcCtD
Ziprasidone—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	5.97e-05	0.000242	CcSEcCtD
Ziprasidone—Rash—Delavirdine—acquired immunodeficiency syndrome	5.95e-05	0.000241	CcSEcCtD
Ziprasidone—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	5.94e-05	0.000241	CcSEcCtD
Ziprasidone—Headache—Delavirdine—acquired immunodeficiency syndrome	5.91e-05	0.000239	CcSEcCtD
Ziprasidone—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	5.9e-05	0.000239	CcSEcCtD
Ziprasidone—Nausea—Efavirenz—acquired immunodeficiency syndrome	5.86e-05	0.000237	CcSEcCtD
Ziprasidone—Dizziness—Ritonavir—acquired immunodeficiency syndrome	5.77e-05	0.000234	CcSEcCtD
Ziprasidone—Asthenia—Lamivudine—acquired immunodeficiency syndrome	5.75e-05	0.000233	CcSEcCtD
Ziprasidone—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	5.75e-05	0.000233	CcSEcCtD
Ziprasidone—Nausea—Delavirdine—acquired immunodeficiency syndrome	5.6e-05	0.000227	CcSEcCtD
Ziprasidone—Dizziness—Saquinavir—acquired immunodeficiency syndrome	5.55e-05	0.000225	CcSEcCtD
Ziprasidone—Vomiting—Ritonavir—acquired immunodeficiency syndrome	5.55e-05	0.000225	CcSEcCtD
Ziprasidone—Rash—Ritonavir—acquired immunodeficiency syndrome	5.5e-05	0.000223	CcSEcCtD
Ziprasidone—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	5.5e-05	0.000222	CcSEcCtD
Ziprasidone—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	5.48e-05	0.000222	CcSEcCtD
Ziprasidone—Headache—Ritonavir—acquired immunodeficiency syndrome	5.47e-05	0.000221	CcSEcCtD
Ziprasidone—Vomiting—Saquinavir—acquired immunodeficiency syndrome	5.34e-05	0.000216	CcSEcCtD
Ziprasidone—Dizziness—Lamivudine—acquired immunodeficiency syndrome	5.3e-05	0.000214	CcSEcCtD
Ziprasidone—Rash—Saquinavir—acquired immunodeficiency syndrome	5.29e-05	0.000214	CcSEcCtD
Ziprasidone—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	5.29e-05	0.000214	CcSEcCtD
Ziprasidone—Headache—Saquinavir—acquired immunodeficiency syndrome	5.26e-05	0.000213	CcSEcCtD
Ziprasidone—Nausea—Ritonavir—acquired immunodeficiency syndrome	5.18e-05	0.00021	CcSEcCtD
Ziprasidone—Vomiting—Lamivudine—acquired immunodeficiency syndrome	5.09e-05	0.000206	CcSEcCtD
Ziprasidone—Rash—Lamivudine—acquired immunodeficiency syndrome	5.05e-05	0.000204	CcSEcCtD
Ziprasidone—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	5.05e-05	0.000204	CcSEcCtD
Ziprasidone—Headache—Lamivudine—acquired immunodeficiency syndrome	5.02e-05	0.000203	CcSEcCtD
Ziprasidone—Nausea—Saquinavir—acquired immunodeficiency syndrome	4.99e-05	0.000202	CcSEcCtD
Ziprasidone—Nausea—Lamivudine—acquired immunodeficiency syndrome	4.76e-05	0.000193	CcSEcCtD
Ziprasidone—HTR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.37e-05	0.000197	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.36e-05	0.000196	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.33e-05	0.000192	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.33e-05	0.000192	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.33e-05	0.000192	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.33e-05	0.000191	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.32e-05	0.000191	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.32e-05	0.000191	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.31e-05	0.000189	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.31e-05	0.000189	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.31e-05	0.000189	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.31e-05	0.000188	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.31e-05	0.000188	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.3e-05	0.000188	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.3e-05	0.000188	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.3e-05	0.000188	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.3e-05	0.000188	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.3e-05	0.000187	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.29e-05	0.000186	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.29e-05	0.000186	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.29e-05	0.000186	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.29e-05	0.000186	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.29e-05	0.000186	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.29e-05	0.000186	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.29e-05	0.000185	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.29e-05	0.000185	CbGpPWpGaD
Ziprasidone—HTR6—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.28e-05	0.000185	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.28e-05	0.000185	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.28e-05	0.000185	CbGpPWpGaD
Ziprasidone—HTR7—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.28e-05	0.000185	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.28e-05	0.000185	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.28e-05	0.000185	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.28e-05	0.000185	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.28e-05	0.000184	CbGpPWpGaD
Ziprasidone—HTR1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.28e-05	0.000184	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.27e-05	0.000183	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.27e-05	0.000183	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.27e-05	0.000182	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.26e-05	0.000182	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.25e-05	0.00018	CbGpPWpGaD
Ziprasidone—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.25e-05	0.00018	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.25e-05	0.00018	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.25e-05	0.00018	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.25e-05	0.00018	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.23e-05	0.000177	CbGpPWpGaD
Ziprasidone—DRD4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.23e-05	0.000177	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.23e-05	0.000177	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.23e-05	0.000177	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.23e-05	0.000177	CbGpPWpGaD
Ziprasidone—CHRM4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.21e-05	0.000175	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.2e-05	0.000173	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.2e-05	0.000172	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.19e-05	0.000172	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.19e-05	0.000172	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.19e-05	0.000172	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.18e-05	0.000171	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.18e-05	0.000171	CbGpPWpGaD
Ziprasidone—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	1.18e-05	0.00017	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.18e-05	0.00017	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.18e-05	0.00017	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.18e-05	0.00017	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.17e-05	0.000169	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.17e-05	0.000169	CbGpPWpGaD
Ziprasidone—HTR6—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.17e-05	0.000168	CbGpPWpGaD
Ziprasidone—HTR7—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.17e-05	0.000168	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.16e-05	0.000167	CbGpPWpGaD
Ziprasidone—CHRM5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.16e-05	0.000167	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.16e-05	0.000167	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.16e-05	0.000167	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.16e-05	0.000167	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.14e-05	0.000164	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.14e-05	0.000164	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.13e-05	0.000163	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.13e-05	0.000163	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.13e-05	0.000163	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.13e-05	0.000162	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.12e-05	0.000162	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.12e-05	0.000162	CbGpPWpGaD
Ziprasidone—DRD4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.12e-05	0.000161	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.11e-05	0.00016	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.11e-05	0.00016	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.11e-05	0.00016	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.11e-05	0.00016	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.11e-05	0.00016	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.11e-05	0.000159	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.11e-05	0.000159	CbGpPWpGaD
Ziprasidone—DRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.11e-05	0.000159	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.1e-05	0.000159	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.1e-05	0.000159	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.1e-05	0.000159	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.09e-05	0.000157	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.09e-05	0.000157	CbGpPWpGaD
Ziprasidone—DRD3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.09e-05	0.000157	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.09e-05	0.000157	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.09e-05	0.000157	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.08e-05	0.000155	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.08e-05	0.000155	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.05e-05	0.000152	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.03e-05	0.000148	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.02e-05	0.000146	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.01e-05	0.000146	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.01e-05	0.000146	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.01e-05	0.000146	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.01e-05	0.000145	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1e-05	0.000145	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1e-05	0.000145	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1e-05	0.000144	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.91e-06	0.000143	CbGpPWpGaD
Ziprasidone—ADRA2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.85e-06	0.000142	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.8e-06	0.000141	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.75e-06	0.00014	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.66e-06	0.000139	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.61e-06	0.000138	CbGpPWpGaD
Ziprasidone—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.51e-06	0.000137	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.48e-06	0.000137	CbGpPWpGaD
Ziprasidone—HTR2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.46e-06	0.000136	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.34e-06	0.000135	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.33e-06	0.000134	CbGpPWpGaD
Ziprasidone—ADRA2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.2e-06	0.000133	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.19e-06	0.000132	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.15e-06	0.000132	CbGpPWpGaD
Ziprasidone—ADRA1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.06e-06	0.00013	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.95e-06	0.000129	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.93e-06	0.000129	CbGpPWpGaD
Ziprasidone—DRD5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.89e-06	0.000128	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.83e-06	0.000127	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.79e-06	0.000127	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.64e-06	0.000124	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.61e-06	0.000124	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.59e-06	0.000124	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.55e-06	0.000123	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.48e-06	0.000122	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.47e-06	0.000122	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.45e-06	0.000122	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.42e-06	0.000121	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.41e-06	0.000121	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.4e-06	0.000121	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.36e-06	0.00012	CbGpPWpGaD
Ziprasidone—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.35e-06	0.00012	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.34e-06	0.00012	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.32e-06	0.00012	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.31e-06	0.00012	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.3e-06	0.000119	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.29e-06	0.000119	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.27e-06	0.000119	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.23e-06	0.000118	CbGpPWpGaD
Ziprasidone—HTR2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.22e-06	0.000118	CbGpPWpGaD
Ziprasidone—HRH1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.2e-06	0.000118	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.19e-06	0.000118	CbGpPWpGaD
Ziprasidone—CHRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.17e-06	0.000118	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.17e-06	0.000118	CbGpPWpGaD
Ziprasidone—CHRM3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.15e-06	0.000117	CbGpPWpGaD
Ziprasidone—CHRM2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.07e-06	0.000116	CbGpPWpGaD
Ziprasidone—ADRA1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.05e-06	0.000116	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.75e-06	0.000112	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.7e-06	0.000111	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.63e-06	0.00011	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.61e-06	0.00011	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.59e-06	0.000109	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.59e-06	0.000109	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.58e-06	0.000109	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.56e-06	0.000109	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—ALB—acquired immunodeficiency syndrome	7.5e-06	0.000108	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.49e-06	0.000108	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.48e-06	0.000108	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.47e-06	0.000108	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.46e-06	0.000107	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.45e-06	0.000107	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.42e-06	0.000107	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.4e-06	0.000107	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	7.33e-06	0.000106	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.33e-06	0.000106	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.31e-06	0.000105	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—ALB—acquired immunodeficiency syndrome	7.28e-06	0.000105	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.94e-06	0.0001	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.89e-06	9.93e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.89e-06	9.92e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.86e-06	9.88e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.85e-06	9.87e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.84e-06	9.85e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.81e-06	9.8e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.79e-06	9.78e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.7e-06	9.65e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.66e-06	9.6e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.59e-06	9.49e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.56e-06	9.45e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.5e-06	9.37e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.47e-06	9.32e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—ALB—acquired immunodeficiency syndrome	6.45e-06	9.28e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.23e-06	8.97e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.2e-06	8.92e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.93e-06	8.55e-05	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.93e-06	8.54e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	5.91e-06	8.52e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.9e-06	8.5e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.85e-06	8.43e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.83e-06	8.39e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	5.42e-06	7.81e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.29e-06	7.61e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.26e-06	7.57e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.25e-06	7.56e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.1e-06	7.35e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.08e-06	7.31e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.08e-06	7.31e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.05e-06	7.27e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.94e-06	7.11e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.91e-06	7.08e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.86e-06	7e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.83e-06	6.96e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.48e-06	6.45e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.46e-06	6.42e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.41e-06	6.35e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.4e-06	6.34e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.39e-06	6.32e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.38e-06	6.31e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.38e-06	6.3e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.37e-06	6.29e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.36e-06	6.28e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.35e-06	6.26e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.33e-06	6.23e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.32e-06	6.22e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.31e-06	6.2e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.29e-06	6.19e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.05e-06	5.84e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.05e-06	5.83e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.02e-06	5.79e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.01e-06	5.78e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.99e-06	5.75e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.94e-06	5.67e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.87e-06	5.58e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	3.85e-06	5.55e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.82e-06	5.5e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.66e-06	5.27e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.49e-06	5.02e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.44e-06	4.96e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	3.26e-06	4.7e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.11e-06	4.47e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3e-06	4.32e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.98e-06	4.3e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.9e-06	4.18e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.86e-06	4.11e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.63e-06	3.79e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.59e-06	3.73e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.59e-06	3.72e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.58e-06	3.71e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.57e-06	3.7e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.54e-06	3.66e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.54e-06	3.65e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	2.52e-06	3.63e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.36e-06	3.39e-05	CbGpPWpGaD
